Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer

13 May 2022

Abstract excerpt

Abstract Intrinsic and acquired anti-HER2 resistance remains a major hurdle for treating HER2-positive breast cancer. Using genome-wide CRISPR/Cas9 screening in vitro and in vivo, we identify FGFR4 as an essential gene following anti-HER2 treatment. FGFR4 inhibition enhances susceptibility to anti-HER2 therapy in resistant breast cancer. Mechanistically, m6A-hypomethylation regulated FGFR4 phosphorylates GSK-3β...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Ferroptosis and cancer prognosis
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35562334
DOI: 10.1038/s41467-022-30217-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancerPMID 35562334Read ↗

Dysregulation of Labile Iron Predisposes Chemotherapy Resistant Cancer Cells to FerroptosisSemantic proximity Read ↗

Dysregulation of cellular iron predisposes chemotherapy resistant cancer cells to ferroptosisSemantic proximity Read ↗

Genetic mutations governing ferroptosis sensitivity and resistance: a precision approach to cancer therapy.Semantic proximity Read ↗

Ferroptosis resistance in cancer: recent advances and future perspectivesSemantic proximity Read ↗

NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8Semantic proximity Read ↗

Targeting Riboflavin Kinase Induces Ferroptosis and Apoptosis in Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting NRF2 and FSP1 to Overcome Ferroptosis Resistance in <em>TSC2</em>-Deficient and Cancer CellsSemantic proximity Read ↗

CRISPR/Cas9-mediated knockout of Lcn2 in human breast cancer cell line MDA-MB-231 ameliorates erastin-mediated ferroptosis and increases cisplatin vulnerabilitySemantic proximity Read ↗

Targeting NRF2 and FSP1 to Overcome Ferroptosis Resistance in TSC2-Deficient and Cancer CellsSemantic proximity Read ↗

Single-cell analysis reveals that MXRA8 affected the progression of breast cancer via regulating ferroptosisSemantic proximity Read ↗

Ferroptosis Resistance: Redundant Antioxidant Networks Is a Barrier to Cancer TherapySemantic proximity Read ↗

Eliminating Aggressive Cancers via PROTAC-like Inducers of FerroptosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.